Document Detail


A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.
MedLine Citation:
PMID:  16227145     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previous prospective outcome studies of statins have not provided any guidance on benefit-risk in patients with heart failure.
AIM: The primary objective is to determine whether rosuvastatin (10 mg) reduces the combined endpoint of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke (time to first event). The first secondary endpoint is all-cause mortality.
METHODS: CORONA is a randomized, double-blind, placebo-controlled trial. Briefly, men and women, aged > or =60 years with chronic symptomatic systolic heart failure of ischemic aetiology and ejection fraction < or =0.40 (NYHA class III and IV) or < or =0.35 (NYHA class II) were eligible if they were not using or in need of cholesterol lowering drugs.
RESULTS: Mean age was 73 years (n=5016; 24% women), with 37% in NYHA II and 62% in NYHA III, ejection fraction 0.31, total cholesterol 5.2 mmol/L. Sixty percent have a history of myocardial infarction, 63% hypertension, and 30% diabetes. Patients are well treated for heart failure with 90% on loop or thiazide diuretics, 42% aldosterone antagonists, 91% ACE inhibitor or AT-I blocker, 75% beta-blockers, and 32% digitalis.
CONCLUSION: CORONA is important for three main reasons: (1) A positive result is very important because of the high risk of the population studied, the increasing prevalence of elderly patients with chronic symptomatic systolic heart failure in our society, and the health economic issues involved. (2) If negative, new mechanistic questions about heart failure have to be raised. (3) If neutral we can avoid unnecessary polypharmacy.
Authors:
John Kjekshus; Peter Dunselman; Malin Blideskog; Christina Eskilson; Ake Hjalmarson; John V McMurray; Finn Waagstein; Hans Wedel; Peter Wessman; John Wikstrand;
Related Documents :
9120665 - Concomitant diseases in elderly hypertensives: the position of nicardipine.
12556735 - Improving perioperative outcomes in patients with end-stage heart failure.
20477515 - Biomarkers of risk stratification in congestive heart failure: north american view.
12858125 - Treatment of hypertension for patients with diastolic dysfunction.
7356855 - Effect of intravenous propranolol on qt interval. a new method of assessment.
19571535 - Elevated troponin after stroke: a systematic review.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of heart failure     Volume:  7     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-17     Completed Date:  2006-01-23     Revised Date:  2011-06-08    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1059-69     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Rikshospitalet University Hospital, University of Oslo, Sognsvannsveien 20, Oslo 0027, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Aged
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Fluorobenzenes / administration & dosage*
Follow-Up Studies
Heart Failure / diagnosis,  drug therapy*,  mortality*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Hypercholesterolemia / diagnosis,  drug therapy*,  mortality*
International Cooperation
Male
Middle Aged
Probability
Prospective Studies
Pyrimidines / administration & dosage*
Risk Assessment
Severity of Illness Index
Sulfonamides / administration & dosage*
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pre-eclampsia with acute heart failure postpartum as primary manifestation of systemic lupus erythem...
Next Document:  Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study...